Most readers would already be aware that Carl Zeiss Meditec's (ETR:AFX) stock increased significantly by 19% over ...

Carl Zeiss Meditec appears to be overvalued by 25% at the moment, based on our discounted cash flow valuation. The stock is currently priced at €70.85 on the market compared to our intrinsic value of ...

View Carl Zeiss Meditec AG (CZMWY) current and estimated P/E ratio data provided by Seeking Alpha.

ZEISS VisioGen offers a cutting-edge, AI-driven solution designed to enhance refractive patient communication and streamline ...

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Carl Zeiss Meditec AG and its affiliates do not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the ...

signed a “Business Cooperation Agreement” with German optical electronic systems company Carl Zeiss AG, with the aim of launching mass production of next-generation holographic head-up ...

Carl Zeiss AG has again opted for continuity in the new appointments of Executive Board members and contract extensions. Thus ...